Based on the importance of exemestane in the treatment of breast cancer, a number of exemestane derivatives were previously synthesized involving modification of C-6 methylene and reduction of C-17 keto group, and evaluated for their aromatase inhibitory potential [16-19]. Here, CYP19A1 is linked to breast carcinoma.